DC
AZN icon

Deschaine & Company’s AstraZeneca AZN Stock Holding History

Deschaine & Company’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$1.88M Buy
29,439
+524
+2% +$35.9K 2.95% 7
2015
Q1 		$1.98M Sell
28,915
-1,165
-4% -$80.9K 3.26% 4
2014
Q4 		$2.12M Buy
+30,080
New +$2.15M 3.19% 4

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Deschaine & Company's AZN Position: Q2 2015 in Review

Deschaine & Company increased its AstraZeneca (AZN) stake by 1.8% in Q2 2015, buying an estimated $35.9K and bringing the position to 29,439 shares worth $1.88M. The position accounts for 2.95% of the portfolio, ranked #7.

Deschaine & Company first reported a position in AZN in Q4 2014 and has held it in 3 quarters since. The position peaked at $2.12M in Q4 2014. 376 funds tracked by Wall St. Rank hold AZN as of Q2 2015.

  • Deschaine & Company held 29,439 shares of AstraZeneca worth $1.88M as of Q2 2015.
  • Deschaine & Company bought 524 AstraZeneca shares in Q2 2015, an estimated $35.9K.
  • AstraZeneca made up 2.95% of Deschaine & Company's portfolio in Q2 2015, its #7 holding.
  • Deschaine & Company first reported a position in AstraZeneca in Q4 2014 and has held it in 3 quarters since.
  • Deschaine & Company's AstraZeneca position peaked at $2.12M in Q4 2014.
  • 376 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2015.

Based on Deschaine & Company's 13F filing for Q2 2015, filed 30 Jul 2015.